The article explains how sealing air leaks first helps insulation improve comfort, energy performance, and moisture control. CLARKS SUMMIT, Pa., Oct. 25, 2026 -- Why should you air seal your home before adding insulation? A HelloNation article featuring insights from...
Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).1,2 Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005).1,2 Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below).1,2 No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable.1,2 These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.1,2
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 1
TAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing TAGRISSO as backbone therapy across EGFRm lung cancer WILMINGTON, Del., October 25, 2026 --( BUSINESS WIRE
SAN DIEGO, Oct. 25, 2026 -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, all dates inclusive (the "Class Period"), have until Monday, November 2, 2026 to...
Did you buy FLNC securities between November 24, 2025 and September 16, 2026? Affected FLNC Investor Summary Who: Fluence Energy, Inc. (NASDAQ: FLNC) What: Securities fraud class action lawsuit filed Class Period: November 24, 2025 through September 16, 2026 Deadline to Seek Lead...
Cathy Gray of Coffee with Cathy has launched a free Website Narcissistic Test that scans web pages and calculates a ratio of company-centric to customer-centric words, helping users assess and improve their website copy.
Developing effective school leaders requires more than preparing educators for administrative responsibilities. It also involves building their capacity to support teachers, navigate organizational challenges, make informed decisions, and create school environments where students…
New class action for Endava plc (DAVA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/30/2026
The case alleges Millrose and certain of its top executives made false and/or misleading statement to investors.
Gas and diesel prices will soon drop rapidly thanks to President Donald J. Trump’s bold actions to unleash American Energy. On day one, the Trump Administration began dismantling the failed Biden-era anti-energy policies, cutting red tape, and ending the Democrats’ Green New Scam agenda. Today, under President Trump’s leadership, America is producing record amounts of […] The post President Trump Secures Major Deals to Unleash American Energy and Cut Gas Prices at the Pump appeared first on The White House.
SAN DIEGO, Oct. 25, 2026 -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Gildan Activewear Inc. (NYSE: GIL) publicly traded securities between February 19, 2025 and June 15, 2026, both dates inclusive (the "Class Period"), have...